Compare Abeona Therapeutics Inc (ABEO) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Jones Lang LaSalle Inc — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while Jones Lang LaSalle Inc trades at $325.79 (market cap $15.43B). The key difference: Jones Lang LaSalle Inc is far larger — about 41.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | JLL | |
|---|---|---|
Market Cap | $373.32M | $15.43B |
Sector | Health | Real Estate |
52-Week High | $7.23 | $358.66 |
52-Week Low | $4.17 | $248.95 |
Enterprise Value | $228.22M | $18.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
JLL trades at $332.57, up 1.56% today, with a bullish technical outlook and strong earnings momentum after beating Q1 2026 EPS estimates. Revenue grew to $26.12B in 2025, with net income reaching $792.10M and improving margins. Positive analyst sentiment includes a $405.50 consensus price target, and recent news highlights strategic growth initiatives and inclusion on Zacks Strong Buy lists as of June 2026.
The stock presents a favorable risk-reward profile with a 22% upside to the consensus target, supported by robust cash flow generation and debt reduction. Key risks include economic sensitivity and competitive pressures, but institutional backing and consistent earnings beats underpin a constructive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
